Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (66,048)	$ (19,101)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense	8,347	2,044
Shares issued for services		124
Research and development expenses - license acquired	5,637	192
Change in fair value of warrant liability	517	223
Change in fair value of convertible notes payable	(230)
Change in fair value of derivative liability	369
Gain on forgiveness of note payable	(149)
Net loss on extinguishment of convertible debt	2,387
Amortization of debt discount	1,582	150
Changes in operating assets and liabilities
Prepaid expenses and other current assets	(2,894)	(791)
Accounts payable	(194)	1,091
Accrued expenses	1,806	5
Licenses payable	(125)	(4,850)
Net cash used in operating activities	(48,995)	(20,913)
Cash flows provided by financing activities
Payment of convertible note	(13,551)
Proceeds from issuance of common stock, net of issuance costs	97,957	8,850
Proceeds from issuance of common stock and convertible notes payable	20,203	10,907
Proceeds from issuance of common stock and warrants, pursuant to          Securities Purchase Agreement, net of issuance costs		6,365
Proceeds from exercise of warrants	7,252	45
Proceeds from exercise of options	102
Proceeds from sales of common stock under ESPP	104
Proceeds from note payable		147
Net cash provided by financing activities	112,067	26,314
Net increase in cash	63,072	5,401
Cash, beginning of period	15,662	10,261
Cash, end of period	78,734	15,662
Supplemental disclosure of cash flow information:
Cash paid for interest	10	11
Cash paid for income taxes
Non-cash investing and financing activities:
Reclass of warrant liabilities related to Series A warrants exercised for cash	1,155	124
Right-of-use assets obtained in exchange for operating lease liabilities	75
Issuance of common stock for convertible notes	69
Issuance of common stock for settlement of debt	1,377
Extinguishment of beneficial conversion feature	1,519
Issuance of common stock for iX Biopharma license	4,832
Issuance of common stock for license payable		$ 2,443